


## PHARMACEUTICAL 2023



## Bolt Biotherapeutics Inc. Rank 159 of 446





## PHARMACEUTICAL 2023



## Bolt Biotherapeutics Inc. Rank 159 of 446

The relative strengths and weaknesses of Bolt Biotherapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Bolt Biotherapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 36% points. The greatest weakness of Bolt Biotherapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 14% points.

The company's Economic Capital Ratio, given in the ranking table, is 145%, being 102% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	172,746
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	23,118
Liabilities, Non-Current	20,262
Other Assets	48,608
Other Compr. Net Income	-598
Other Expenses	0
Other Liabilities	12,921
Other Net Income	2,223
Other Revenues	5,729
Property and Equipment	6,453
Research and Development	73,123
Selling, General and Administrative Expense	22,927

Output Variable	Value in 1000 USD
Assets	227,807
Liabilities	56,301
Expenses	96,050
Revenues	5,729
Stockholders Equity	171,506
Net Income	-88,098
Comprehensive Net Income	-88,397
Economic Capital Ratio	145%

